Darren Incorvaia

2 days ago | fiercebiotech.com | Darren Incorvaia

The federal government is slashing $450 million in grant funding to Harvard University, adding on to the $2.2 billion that has already been cut, according to a May 13 statement from the U.S. Department of Health and Human Services (HHS). The decision to revoke further funding stems in part from recent accusations from the Trump administration that the Harvard Law Review discriminated against white applicants when choosing which articles to publish and members to admit.

3 days ago | fiercebiotech.com | Darren Incorvaia

North Carolina-based CRO Fortrea is saying goodbye to its CEO. Thomas Pike is hitting the road effective May 13 and will be replaced in the interim by Peter Neupert, Fortrea’s lead independent director. A search for Pike’s permanent successor is already in the advanced stages, Fortrea said in a May 12 release. Pike will stay at the company as a consultant to help with the leadership transition. Fortrea was spun out of Labcorp in July 2023 with Pike at the helm.

3 days ago | fiercebiotech.com | Darren Incorvaia

The founder and former leader of Inhibikase Therapeutics is blazing a new biotech trail in an effort to get a beleaguered Parkinson’s candidate over the finish line. Milton Werner, Ph.D., is the founder and CEO of newly launched ABLi Therapeutics, which aims to develop a candidate called risvodetinib as a disease-modifying therapy for Parkinson’s and other diseases of the Abelson Tyrosine Kinases (c-Abl).

3 days ago | fiercebiotech.com | Darren Incorvaia

California biotech NGM Bio is slimming down as the company pivots focus, shedding around 75% of staff, pausing development of a phase 2 liver disease asset and halting further investment in discovery and preclinical work, the company confirmed in a statement to Fierce Biotech. The company’s CEO David Woodhouse, Ph.D., has also voluntarily decided to step down, with Vice President of Corporate Development Diana Peng Bockus stepping up to take his place.

6 days ago | fiercebiotech.com | Darren Incorvaia

Eli Lilly is investing more in its home state of Indiana, pumping up to $250 million more into an existing collaboration with Purdue University over the next eight years. The boosted pact with the boilermakers will focus on artificial intelligence drug discovery methods, speeding up the process of moving drugs through clinical trials and into regulatory approval and manufacturing and enhancing the Indiana life sciences workforce, according to a May 9 release.